Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Dow Jones Today: Stock Indexes Little Changed; Nvidia, Retail Giants to Report Results This Week
11:00am, Monday, 17'th Nov 2025
Major stock indexes were little changed to begin the week, which will see AI darling Nvidia and retail giants Walmart, Home Depot, Lowe's, and Target report quarterly results.
Novo Nordisk is now offering its anti-obesity drug for as low as $199 per month
10:19am, Monday, 17'th Nov 2025
Novo Nordisk (NYSE: NVO) has announced sweeping price cuts for its blockbuster GLP-1 drugs, Wegovy and Ozempic, offering patients access to the lowest doses for just $199/month. New cash-paying patien
Monthly Ozempic Cost Slashed After Trump Deal
10:15am, Monday, 17'th Nov 2025
Novo Nordisk and Eli Lilly will lower the price Medicare pays for their GLP-1 treatments, which cost up to $1,350 per month before insurance, to $245 per month. Patients using the new TrumpRx.gov to p
How Novo Nordisk Just Undercut Eli Lilly And The Trump Administration
09:44am, Monday, 17'th Nov 2025
Novo Nordisk undercut Eli Lilly and the Trump administration on Monday, slashing the cash price of its Wegovy and Ozempic.
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
08:58am, Monday, 17'th Nov 2025
Bagsværd, Denmark, 17 November 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated
Novo Nordisk Cuts Prices for Obesity Drugs
08:56am, Monday, 17'th Nov 2025
The Denmark-based company slashed prices for the first two monthly doses of Wegovy and Ozempic for those who pay cash for the treatments between Nov. 17 and March 31.
Novo Nordisk cuts direct-to-consumer prices for Wegovy, Ozempic to $349 a month
08:11am, Monday, 17'th Nov 2025
Novo Nordisk said it is lowering the direct-to-consumer prices of its blockbuster weight loss drug Wegovy and diabetes counterpart Ozempic to $349 per month from $499 per month for existing cash-payin
Novo Nordisk rolls out $349 Wegovy cash price ahead of plan
07:55am, Monday, 17'th Nov 2025
Novo Nordisk said on Monday it has begun selling its popular weight-loss drug Wegovy for $349 a month to cash payers, months ahead of the timeline set out with the Trump administration.
Novo Nordisk CEO says White House deal aims to bring Wegovy to Medicare patients
04:57am, Monday, 17'th Nov 2025
Wegovy-maker Novo Nordisk's CEO said on Monday a deal with the White House to slash prices on its popular weight‑loss drugs aimed to broaden access to the U.S. Medicare programme, a federal health i
PGIM Jennison Health Sciences Fund Q3 2025 Contributors And Detractors
02:31pm, Sunday, 16'th Nov 2025
The S&P 1500 Health Care Index advanced 4.0% in the third quarter, underperforming the S&P 500, which gained 8.1%. Stock selection within biotechnology and health care providers & services, along with
Wegovy and Zepbound are certain to be top sellers if the federal drug marketplace is launched. The two medications, and others, are set to be priced very advantageously.
Novo Nordisk Stock: Buy And Forget
05:11pm, Friday, 14'th Nov 2025
Novo Nordisk A/S shares have declined more than 50% over the past 12 months. Competition in the obesity and type 2 diabetes market and pricing pressure from the U.S. government have weighed on NVO res
Retail Investors Really Don't Like Novo Nordisk (NVO) Stock
04:13pm, Friday, 14'th Nov 2025
Shares of Novo Nordisk A/S (NYSE: NVO) dropped 1.9%today, closing at $48.25, just a whisker above the 52-week low of $45.05.
Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman
03:19pm, Friday, 14'th Nov 2025
Evan Seigerman, BMO Capital Markets head of health care research, joins 'Power Lunch' to discuss what's behind the recent move in health care stocks, the state of play with GLP-1s and much more.
Novo Nordisk shareholders approve new board chair
08:11am, Friday, 14'th Nov 2025
Novo Nordisk's shareholders have approved Lars Rebien Sorensen as the company's new chairman in an extraordinary shareholder meeting, the company said on Friday.
